Axonics, Inc. (AXNX)
After hours:
| Previous close | 67.33 |
| Open | 67.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 67.14 - 67.50 |
| 52-week range | 47.59 - 69.68 |
| Volume | |
| Avg. volume | 755,331 |
| Market cap | 3.429B |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia
IRVINE, Calif., May 16, 2024--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ recharge-free sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder.
- Business Wire
Axonics Reports First Quarter 2024 Financial Results
IRVINE, Calif., April 30, 2024--Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2024.
- PR Newswire
Boston Scientific Announces Results for First Quarter 2024
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $495 million or $0.33 per share (EPS), compared to $300 million or $0.21 per share a year ago, and achieved adjusted3 EPS of $0.56 for
